Journal Mobile Options
Table of Contents
Vol. 77, No. 1, 2006
Issue release date: July 2006

Adjuvant Chemotherapy in the Management of pT3N0M0 Transitional Cell Carcinoma of the Upper Urinary Tract

Lee S.E. · Byun S.-S. · Park Y.H. · Chang I.H. · Kim Y.J. · Hong S.K.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Introduction: We investigate the efficacy of postoperative adjuvant chemotherapy for locally advanced, but lymph node negative, pathologic stage T3 transitional cell carcinoma (TCC) of the upper urinary tract. Patients and Methods: A retrospective study on 27 patients who had undergone radical nephroureterectomy with regional lymphadenectomy for pT3N0M0 primary upper urinary tract TCC at our institution from 1996 to 2001 was performed. Among the 27 patients, 16 also received adjuvant chemotherapy following surgery (adjuvant group), whereas the other 11 patients did not (nonadjuvant group). Results: Adjuvant and nonadjuvant therapy groups were not significantly different with respect to age, sex, performance status, tumor grade, and tumor location. Overall, 5 of the 16 patients (31%) in the adjuvant group and 4 of the 11 patients (36%) in the nonadjuvant group had recurrence of cancer at 40 months of follow-up. The two groups demonstrated no significant differences in recurrence-free survival (p = 0.794) and disease-specific survival (p = 0.783). Conclusions: Although it would be difficult to draw any definite conclusions from the results of our investigations, our data suggest that adjuvant therapy with traditional conventional chemotherapeutic regimens alone may not be effective as previously anticipated in significantly improving survival rates for locally advanced, but lymph node negative, TCC of the upper urinary tract.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Nocks BN, Heney NM, Daly JJ, Perrone TA, Griffin PP, Prout GR Jr: Transitional cell carcinoma of renal pelvis. Urology 1982;19:472–477.
  2. Reitelman C, Sawczuk IS, Olsson CA, Puchner PJ, Benson MC: Prognostic variables in patients with transitional cell carcinoma of the renal pelvis and proximal ureter. J Urol 1987;138:1144–1145.
  3. Heney NM, Nocks BN, Daly JJ, Blitzer PH, Parkhurst EC: Prognostic factors in carcinoma of the ureter. J Urol 1981;125:632–636.
  4. Bono AV, Benvenuti C, Reali L, Pozzi E, Gibba A, Cosciani-Cunico S, Comuzzi U, Anselmo G: Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res 1989;303:533–540.
  5. Rübben H, Otto T: Locally advanced or metastatic bladder carcinoma: current aspects of therapy. Urologe A 2001;40:464–467.
  6. Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, Markwalder R, Senn E, Sonntag RW: Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994;152:81–84.
  7. Lehmann J, Retz M, Stöckle M: Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy. World J Urol 2002;20:144–150.
  8. Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W: Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol 2004;172(4 Pt 1):1271–1275.
  9. Park S, Hong B, Kim CS, Ahn H: The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol 2004;171(2 Pt 1):621–625.
  10. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52:594–601.
  11. Yoshimura K, Arai Y, Fujimoto H, Nishiyama H, Ogura K, Okino T, Ogawa O: Prognostic impact of extensive parenchymal invasion pattern in pT3 renal pelvic transitional cell carcinoma. Cancer 2002;94:3150–3156.
  12. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459–464.
  13. Freiha F, Reese J, Torti FM: A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155:495–499.
  14. Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thuroff JW, Huber C, Hohenfellner R: Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;148(2 Pt 1):302–306.
  15. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576–3583.
  16. Bamias A, Deliveliotis Ch, Fountzilas G, Gika D, Anagnostopoulos A, Zorzou MP, Kastritis E, Constantinides C, Kosmidis P, Dimopoulos MA: Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol 2004;22:2150–2154.
  17. Mead GM, Roberts JT: The role of the nonsurgical oncologist in the management of advanced transitional cell cancer. I. Locally advanced disease. BJU Int 2004;94:977–980.
  18. Guinan P, Vogelzang NJ, Randazzo R, Sener S, Chmiel J, Fremgen A, Sylvester J: Renal pelvic cancer: a review of 611 patients treated in Illinois 1975–1985. Cancer Incidence and End Results Committee. Urology 1992;40:393–399.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50